No abstract available
MeSH terms
-
Antibodies, Bispecific / administration & dosage
-
Antibodies, Bispecific / adverse effects
-
Antibodies, Bispecific / drug effects*
-
Antineoplastic Agents, Immunological / administration & dosage
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Combined Modality Therapy
-
Consolidation Chemotherapy
-
Hematopoietic Stem Cell Transplantation* / adverse effects
-
Hematopoietic Stem Cell Transplantation* / methods
-
Humans
-
Oncogene Proteins, Fusion / genetics*
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / mortality
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy*
-
Transplantation, Homologous
-
Treatment Outcome
Substances
-
Antibodies, Bispecific
-
Antineoplastic Agents, Immunological
-
Oncogene Proteins, Fusion
-
TCF3-HLF fusion protein, human
-
blinatumomab